---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009383"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:49:55.981168+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma Q3 revenue $22.7M (-6% YoY); net loss narrows to $7.2M

## Summary
- Total net revenue $22.7M, down 6% from $24.2M; net loss ($7.2M) vs ($53.3M) last year.
- Record total prescriptions 153,452 (+32% YoY); ADHD prescriptions up 27%.
- Rx segment revenue $13.8M; ADHD revenue down 21% to $8.3M due to $1.2M channel inventory adjustment.
- Pediatric products revenue up 81% to $5.3M; Consumer Health down 14% to $8.9M.
- Gross margin improved to 56% from 52%; cash $19.2M; FDA approval for Adzenys manufacturing transfer.

## SEC filing metadata
- accession: 0001558370-23-009383
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837023009383/0001558370-23-009383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837023009383/aytu-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009383
- JSON: https://secwatch.observer/filing/0001558370-23-009383.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009383.txt

## Key facts
- Earnings Releases
  AYTU BIOPHARMA, INC reported the quarter ended March 31, 2023 results: revenue $22.7 million, net income $(7.2) million, EPS ($1.93) per share.
  - Period: the quarter ended March 31, 2023
  - Revenue: $22.7 million
  - Net income: $(7.2) million
  - EPS: ($1.93) per share
  - Result: reported results
  source text: Q3 2023 Commercial Highlights (3 months ending March 31, 2023) ● Total net revenue was $22.7 million, a decrease of 6% from the $24.2 million in net revenue in the year-ago quarter. Revenue during Q3 2023 was impacted by a one-time $1.2 million channel inventory adjustment due to an ADHD products price increase instituted on April 1, 2023. Excluding this impact, net revenue would have been $23.9 million, in-line with the year-ago quarter. ● Record total quarterly prescriptions of 153,452, a 32% increase over Q3 2022. ● Net revenue from the Company’s Rx segment was $13.8 million during Q3 2023 compared to $13.9 million in the year-ago quarter. o ADHD products (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue decreased by 21% to $8.3 million from $10.4 million in the year ago quarter. o Pediatric products (Poly-Vi-Flor®, Tri-Vi-Flor®, and Karbinal® ER) net revenue increased 81% to $5.3 million, from $2.9 million in the year-ago quarter. ● Consumer Health revenue during Q3 2023 was $8.9
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837023009383/0001558370-23-009383-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.